StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

A federal jury in California has determined that Eli Lilly must pay Nektar Therapeutics $90 million for breaking an ​agreement related to an autoimmune drug candidate that the ‌companies developed together, according to a Nektar filing with the US Securities and Exchange Commission.

Nektar Therapeutics wins US$90M jury award

Nektar's US$90M jury verdict covers Lilly's breach of a good faith covenant; interest remains for the court and any judgment may be appealed.

StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over Eli Lilly (NYSE: LLY) in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop Nektar’s lead pipeline candidate rezpegaldesleuki…

Jury awards Nektar $90M in suit against Lilly

Nektar Therapeutics won $90 million in its lawsuit against Eli Lilly over a fractured licensing deal, a win for the biotech but a far smaller sum than was sought. Jurors in the US District Court ...